Angelini Pharma Completes Catalyst Pharmaceuticals Acquisition To Expand Global Brain Health Business

Angelini Pharma S.p.A., the international pharmaceutical company and part of Angelini Industries, has completed its acquisition of Catalyst Pharmaceuticals, Inc. Following the transaction, Catalyst has officially become part of Angelini Pharma, combining its commercial infrastructure and portfolio of rare disease therapies with Angelini Pharma's expertise in brain health. The acquisition strengthens Angelini Pharma's global presence and establishes a significant foothold in the U.S. pharmaceutical market as part of the company's long-term growth strategy.

To support the acquisition and future expansion, funds managed by Blackstone will invest €1 billion in preferred equity, subject to customary regulatory approvals. In addition, CDP Equity has approved an investment of approximately €1 billion through a capital increase, acquiring a 23.5% stake in Angelini Pharma's common equity. The financing is intended to accelerate the company's growth in brain health and rare diseases, expand research and development activities, strengthen Italy's pharmaceutical industry, and support the creation of high-quality jobs. The transaction was financed with the support of BNP Paribas, while Morgan Stanley served as financial advisor for the investments from Blackstone and CDP Equity.

The acquisition represents a major milestone in Angelini Industries' transformation strategy, which has been underway for the past four years. While expanding its presence in the United States through Catalyst, the company emphasized that Italy will continue to serve as its strategic hub for manufacturing, scientific research, and innovation. The integration of Catalyst is expected to strengthen Angelini Pharma's position as a global company focused on brain health and rare neurological diseases.

Sergio Marullo di Condojanni, Chief Executive Officer of Angelini Pharma, said the completion of the acquisition marks an important step toward building a global, science-driven pharmaceutical company with a strong patient-centered approach. He noted that Catalyst's expertise in rare neurological diseases, together with Angelini Pharma's existing capabilities, will help create a next-generation platform for brain health and rare diseases. He also welcomed the Catalyst team to the organization and thanked Blackstone and CDP Equity for supporting the company's long-term transformation.

Rich Daly, President of Angelini Pharma's newly formed Global Rare Disease Business Unit, said joining Angelini Pharma creates an opportunity to combine the strengths of both organizations while expanding access to treatments for patients living with rare diseases. He added that the new global platform will help accelerate the development and delivery of innovative therapies for patients worldwide.

Representatives from both CDP Equity and Blackstone described the investment as an important step in supporting the international growth of one of Italy's leading pharmaceutical companies. They highlighted the transaction's potential to strengthen innovation, expand global operations, and reinforce Angelini Pharma's long-term position in the life sciences sector while supporting its strategic ambitions in brain health and rare diseases.